Pacira BioSciences Shares Rise 15% on Patent Settlement Over Exparel

Dow Jones

Apr 08, 2025

By Sabela Ojea

Shares of Pacira BioSciences climbed after the company said it entered a settlement agreement regarding the patent litigation for Exparel, a local anesthetic administered at the time of surgery.

The stock was up 15% to $26.25 in postmarket trading. Through Monday's close, shares are up 22% year to date.

The non-opioid pain management company said that the settlement with Fresenius Kabi USA and eVenus Pharmaceuticals Laboratories provides the parties with a license to the patents required to manufacture and sell certain volume-limited amounts of a generic bupivacaine liposome injectable suspension in the U.S. beginning in early 2030.

The license will permit entry of a generic bupivacaine liposome injectable suspension before the July 2, 2044, expiration date of the last-to-expire of the company's orange book-listed patents for Exparel.

Pacira said that it will pay the parties $7 million in connection with expected savings with respect to the avoidance of the fees, among other things.

Write to Sabela Ojea at sabela.ojea@wsj.com

(END) Dow Jones Newswires

April 07, 2025 18:22 ET (22:22 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

LOGIN / SIGN UP

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2525077410"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2525077410\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2525077410?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-04-08 06:22","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2525077410","market":"hk","top_or_hot":-1,"title":"Pacira BioSciences Shares Rise 15% on Patent Settlement Over Exparel","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Sabela Ojea \n</p>\n<pre>\n \n</pre>\n<p>\n  Shares of Pacira BioSciences climbed after the company said it entered a settlement agreement regarding the patent litigation for Exparel, a local anesthetic administered at the time of surgery. \n</p>\n<p>\n  The stock was up 15% to $26.25 in postmarket trading. Through Monday's close, shares are up 22% year to date. \n</p>\n<p>\n  The non-opioid pain management company said that the settlement with Fresenius Kabi USA and eVenus Pharmaceuticals Laboratories provides the parties with a license to the patents required to manufacture and sell certain volume-limited amounts of a generic bupivacaine liposome injectable suspension in the U.S. beginning in early 2030. \n</p>\n<p>\n  The license will permit entry of a generic bupivacaine liposome injectable suspension before the July 2, 2044, expiration date of the last-to-expire of the company's orange book-listed patents for Exparel. \n</p>\n<p>\n  Pacira said that it will pay the parties $7 million in connection with expected savings with respect to the avoidance of the fees, among other things. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Sabela Ojea at sabela.ojea@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  April 07, 2025 18:22 ET (22:22 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pacira BioSciences Shares Rise 15% on Patent Settlement Over Exparel</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPacira BioSciences Shares Rise 15% on Patent Settlement Over Exparel\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-04-08 06:22</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Sabela Ojea \n</p>\n<pre>\n \n</pre>\n<p>\n  Shares of Pacira BioSciences climbed after the company said it entered a settlement agreement regarding the patent litigation for Exparel, a local anesthetic administered at the time of surgery. \n</p>\n<p>\n  The stock was up 15% to $26.25 in postmarket trading. Through Monday's close, shares are up 22% year to date. \n</p>\n<p>\n  The non-opioid pain management company said that the settlement with Fresenius Kabi USA and eVenus Pharmaceuticals Laboratories provides the parties with a license to the patents required to manufacture and sell certain volume-limited amounts of a generic bupivacaine liposome injectable suspension in the U.S. beginning in early 2030. \n</p>\n<p>\n  The license will permit entry of a generic bupivacaine liposome injectable suspension before the July 2, 2044, expiration date of the last-to-expire of the company's orange book-listed patents for Exparel. \n</p>\n<p>\n  Pacira said that it will pay the parties $7 million in connection with expected savings with respect to the avoidance of the fees, among other things. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Sabela Ojea at sabela.ojea@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  April 07, 2025 18:22 ET (22:22 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"制药","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2525077410","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2525077410","pubTimestamp":1744064520,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Shares of Pacira BioSciences climbed after the company said it entered a settlement agreement regarding the patent litigation for Exparel, a local anesthetic administered at the time of surgery.The stock was up 15% to $26.25 in postmarket trading. Through Monday's close, shares are up 22% year to date.The non-opioid pain management company said that the settlement with Fresenius Kabi USA and eVenus Pharmaceuticals Laboratories provides the parties with a license to the patents required to manufacture and sell certain volume-limited amounts of a generic bupivacaine liposome injectable suspension in the U.S. beginning in early 2030.The license will permit entry of a generic bupivacaine liposome injectable suspension before the July 2, 2044, expiration date of the last-to-expire of the company's orange book-listed patents for Exparel.Pacira said that it will pay the parties $7 million in connection with expected savings with respect to the avoidance of the fees, among other things.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4007":"制药","PCRX":"Pacira Pharmaceuticals"},"translate_title":"Pacira BioSciences股价因Exparel专利和解而上涨15%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PCRX":0.9},"content_text":"By Sabela Ojea \n\n\n \n\n\n  Shares of Pacira BioSciences climbed after the company said it entered a settlement agreement regarding the patent litigation for Exparel, a local anesthetic administered at the time of surgery. \n\n\n  The stock was up 15% to $26.25 in postmarket trading. Through Monday's close, shares are up 22% year to date. \n\n\n  The non-opioid pain management company said that the settlement with Fresenius Kabi USA and eVenus Pharmaceuticals Laboratories provides the parties with a license to the patents required to manufacture and sell certain volume-limited amounts of a generic bupivacaine liposome injectable suspension in the U.S. beginning in early 2030. \n\n\n  The license will permit entry of a generic bupivacaine liposome injectable suspension before the July 2, 2044, expiration date of the last-to-expire of the company's orange book-listed patents for Exparel. \n\n\n  Pacira said that it will pay the parties $7 million in connection with expected savings with respect to the avoidance of the fees, among other things. \n\n\n \n\n\n  Write to Sabela Ojea at sabela.ojea@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  April 07, 2025 18:22 ET (22:22 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}